Based on these results, the FDA recently approved ofatumumab for relapsing forms of multiple sclerosis (MS). EMA approval is expected by Q2 2021. In Germany, treatment of MS is not restricted to specialized cen
Evaluating perceptions of ofatumumab in multiple sclerosis via social media listening–early 3 months post approval data. Safety. 2020;13:12. Google Scholar United States Food Drug Administration. Kesimpta – prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125326s...
Evaluating perceptions of ofatumumab in multiple sclerosis via social media listening–early 3 months post approval data. Safety. 2020;13:12. Google Scholar United States Food Drug Administration. Kesimpta – prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125326s...